<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10005">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00702143</url>
  </required_header>
  <id_info>
    <org_study_id>18F-AV-45-A05</org_study_id>
    <nct_id>NCT00702143</nct_id>
  </id_info>
  <brief_title>A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)</brief_title>
  <official_title>An Open Label, Parallel Group, Multicenter Study, Evaluating the Safety and Imaging Characteristics of 18F-AV-45 in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avid Radiopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avid Radiopharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate 18F-AV-45 positron emission tomography (PET) imaging for distinguishing healthy
      control subjects, from subjects with Alzheimer's disease (AD) or Mild cognitive impairment
      (MCI).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Qualitative Amyloid Image Assessment</measure>
    <time_frame>50-60 min after injection</time_frame>
    <safety_issue>No</safety_issue>
    <description>Three readers blinded to all clinical information classified florbetapir-Positron Emission Tomography (PET) images as either positive for amyloid or negative for amyloid. The majority read was the primary efficacy endpoint for the qualitative evaluation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Cortical to Cerebellum SUVR</measure>
    <time_frame>50-60 min after injection</time_frame>
    <safety_issue>No</safety_issue>
    <description>Standardized Uptake Value ratio (SUVR) is the ratio of tracer uptake in predefined cortical regions, relative to uptake in the whole cerebellum.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Positive Florbetapir-PET Scans</measure>
    <time_frame>50-60 min after injection</time_frame>
    <safety_issue>No</safety_issue>
    <description>Three readers blinded to all clinical information classified florbetapir-PET images as either positive for amyloid or negative for amyloid. The majority read was used to determine the proportion of positive scans across the three groups.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">184</enrollment>
  <condition>Alzheimer's Disease</condition>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>AD subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MCI Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MCI (mild cognitive impairment)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>florbetapir F 18</intervention_name>
    <description>IV injection, 370MBq (10mCi), single dose</description>
    <arm_group_label>AD subjects</arm_group_label>
    <arm_group_label>MCI Subjects</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
    <other_name>18F-AV-45</other_name>
    <other_name>Amyvid</other_name>
    <other_name>florbetapir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria AD:

          -  Male or female &gt;=50 years of age

          -  Meet National Institute of Neurological and Communicative Diseases and
             Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS) criteria for
             probable AD with MMSE score of 10-24

        Inclusion Criteria MCI:

          -  Male or female &gt;=50 years of age

          -  Have a Clinical Dementia Rating (CDR) of 0.5

          -  MMSE &gt;24

        Normal subjects:

          -  Male or female &gt;=50 years of age

          -  MMSE &gt;=29

          -  Normal on psychometric test battery at screening

          -  Provide informed consent

        Exclusion Criteria:

          -  Have a history or current diagnosis of other neurologic disease

          -  Have had or currently have a diagnosis of other neurodegenerative disease

          -  Have participated in experimental therapy targeted to amyloid plaque
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chief Medical Officer</last_name>
    <role>Study Director</role>
    <affiliation>Avid Radiopharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85252</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92626</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hallandale Beach</city>
        <state>Florida</state>
        <zip>33064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sunrise</city>
        <state>Florida</state>
        <zip>33351</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jenkintown</city>
        <state>Pennsylvania</state>
        <zip>19046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bennington</city>
        <state>Vermont</state>
        <zip>05201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <lastchanged_date>May 8, 2012</lastchanged_date>
  <firstreceived_date>June 19, 2008</firstreceived_date>
  <firstreceived_results_date>April 6, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognition Disorders</mesh_term>
    <mesh_term>Mild Cognitive Impairment</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AD Subjects</title>
          <description>Probable Alzheimer's Disease (AD) according to the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association criteria</description>
        </group>
        <group group_id="P2">
          <title>MCI Subjects</title>
          <description>MCI (mild cognitive impairment)</description>
        </group>
        <group group_id="P3">
          <title>Healthy Controls</title>
          <description>cognitively normal (healthy) controls</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="78"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AD Subjects</title>
          <description>Probable Alzheimer's Disease (AD) according to the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association criteria</description>
        </group>
        <group group_id="B2">
          <title>MCI Subjects</title>
          <description>MCI (mild cognitive impairment)</description>
        </group>
        <group group_id="B3">
          <title>Healthy Controls</title>
          <description>cognitively normal (healthy) controls</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="45"/>
                <measurement group_id="B2" value="60"/>
                <measurement group_id="B3" value="79"/>
                <measurement group_id="B4" value="184"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="75.4" spread="9.21"/>
                <measurement group_id="B2" value="71.7" spread="10.23"/>
                <measurement group_id="B3" value="69.4" spread="11.04"/>
                <measurement group_id="B4" value="71.6" spread="10.57"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="19"/>
                <measurement group_id="B2" value="33"/>
                <measurement group_id="B3" value="45"/>
                <measurement group_id="B4" value="97"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="26"/>
                <measurement group_id="B2" value="27"/>
                <measurement group_id="B3" value="34"/>
                <measurement group_id="B4" value="87"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="45"/>
                <measurement group_id="B2" value="60"/>
                <measurement group_id="B3" value="79"/>
                <measurement group_id="B4" value="184"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Qualitative Amyloid Image Assessment</title>
        <description>Three readers blinded to all clinical information classified florbetapir-Positron Emission Tomography (PET) images as either positive for amyloid or negative for amyloid. The majority read was the primary efficacy endpoint for the qualitative evaluation.</description>
        <time_frame>50-60 min after injection</time_frame>
        <safety_issue>No</safety_issue>
        <population>One healthy subject received florbetapir F 18 but due to technical difficulties with the scanner was not imaged and is therefore not included in the efficacy population.</population>
        <group_list>
          <group group_id="O1">
            <title>AD Subjects</title>
            <description>Probable Alzheimer's Disease (AD) according to the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association criteria</description>
          </group>
          <group group_id="O2">
            <title>MCI Subjects</title>
            <description>MCI (mild cognitive impairment)</description>
          </group>
          <group group_id="O3">
            <title>Healthy Controls</title>
            <description>cognitively normal (healthy) controls</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="45"/>
                  <measurement group_id="O2" value="60"/>
                  <measurement group_id="O3" value="78"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Qualitative Amyloid Image Assessment</title>
            <description>Three readers blinded to all clinical information classified florbetapir-Positron Emission Tomography (PET) images as either positive for amyloid or negative for amyloid. The majority read was the primary efficacy endpoint for the qualitative evaluation.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Positive for amyloid</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                  <measurement group_id="O2" value="23"/>
                  <measurement group_id="O3" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Negative for amyloid</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="37"/>
                  <measurement group_id="O3" value="67"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Fisher exact test comparing the proportion of amyloid positive subjects between clinical diagnosis groups</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0002</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Fisher exact test comparing the proportion of amyloid positive subjects between clinical diagnosis groups</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.0001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Fisher exact test comparing the proportion of amyloid positive subjects between clinical diagnosis groups</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0014</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Positive Florbetapir-PET Scans</title>
        <description>Three readers blinded to all clinical information classified florbetapir-PET images as either positive for amyloid or negative for amyloid. The majority read was used to determine the proportion of positive scans across the three groups.</description>
        <time_frame>50-60 min after injection</time_frame>
        <safety_issue>No</safety_issue>
        <population>One healthy subject received florbetapir F 18 but due to technical difficulties with the scanner was not imaged and is therefore not included in the efficacy population.</population>
        <group_list>
          <group group_id="O1">
            <title>AD Subjects</title>
            <description>Probable Alzheimer's Disease (AD) according to the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association criteria</description>
          </group>
          <group group_id="O2">
            <title>MCI Subjects</title>
            <description>MCI (mild cognitive impairment)</description>
          </group>
          <group group_id="O3">
            <title>Healthy Controls</title>
            <description>cognitively normal (healthy) controls</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="45"/>
                  <measurement group_id="O2" value="60"/>
                  <measurement group_id="O3" value="78"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Proportion of Positive Florbetapir-PET Scans</title>
            <description>Three readers blinded to all clinical information classified florbetapir-PET images as either positive for amyloid or negative for amyloid. The majority read was used to determine the proportion of positive scans across the three groups.</description>
            <units>percentage of amyoid positive scans</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="75.6" lower_limit="60.5" upper_limit="87.1"/>
                  <measurement group_id="O2" value="38.3" lower_limit="26.1" upper_limit="51.8"/>
                  <measurement group_id="O3" value="14.1" lower_limit="7.3" upper_limit="23.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Cortical to Cerebellum SUVR</title>
        <description>Standardized Uptake Value ratio (SUVR) is the ratio of tracer uptake in predefined cortical regions, relative to uptake in the whole cerebellum.</description>
        <time_frame>50-60 min after injection</time_frame>
        <safety_issue>No</safety_issue>
        <population>One healthy subject received florbetapir F 18 but due to technical difficulties with the scanner was not imaged and is therefore not included in the efficacy population.</population>
        <group_list>
          <group group_id="O1">
            <title>AD Subjects</title>
            <description>Probable Alzheimer's Disease (AD) according to the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association criteria</description>
          </group>
          <group group_id="O2">
            <title>MCI Subjects</title>
            <description>MCI (mild cognitive impairment)</description>
          </group>
          <group group_id="O3">
            <title>Healthy Controls</title>
            <description>cognitively normal (healthy) controls</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="45"/>
                  <measurement group_id="O2" value="60"/>
                  <measurement group_id="O3" value="78"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Cortical to Cerebellum SUVR</title>
            <description>Standardized Uptake Value ratio (SUVR) is the ratio of tracer uptake in predefined cortical regions, relative to uptake in the whole cerebellum.</description>
            <units>SUVR</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.404" spread="0.2670"/>
                  <measurement group_id="O2" value="1.199" spread="0.2761"/>
                  <measurement group_id="O3" value="1.051" spread="0.1585"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis of variance P value testing for an overall difference in the mean cortical SUVR between the clinical diagnostic groups.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of variance contrast P value testing for difference in the mean cortical SUVR</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis of variance contrast P value testing for difference in the mean cortical SUVR</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis of variance contrast P value testing for difference in the mean cortical SUVR</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0003</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs were collected up to 7 days after injection. SAEs were collected up to 30 days after injection.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>All Subjects</title>
          <description>All subjects receiving florbetapir F 18 injection</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Avid Radiopharmaceuticals</organization>
      <phone>215-298-0700</phone>
      <email>clinicaloperations@avidrp.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
